ReviewFrontiers in immunology2026
Connective tissue diseases combined with chronic myelomonocytic leukemia and myelofibrosis: a case report and literature review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Connective tissue disease (CTD) is one of the common autoimmune diseases (AIDs). Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disease characterized by peripheral blood monocytosis and bone marrow dysplasia, and it is frequently associated with autoimmune complications and secondary myelofibrosis (MF). This article reports a 52-year-old male patient with recurrent arthritis and fever as the main manifestations, for whom CTD was initially considered, and who received hormone and immunosuppressant combination therapy for 2 years 10 months. The patient still suffered from recurrent fever and severe anemia; further bone marrow cytology examinations revealed abnormal bone marrow hematopoiesis, and the final diagnosis was CTD complicated with CMML and MF (MF-3 grade). After the patient was transferred to the hematology department, we adopted the azacytidine + ruxolitinib dual-target regimen to simultaneously target autoimmune inflammation, malignant clonal hematopoiesis, and severe myelofibrosis. After treatment, the patient's fever and other systemic symptoms were significantly relieved, monocytosis was corrected, and severe anemia and thrombocytopenia were markedly improved.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.